ImClone drug extends life in head, neck cancer patients (Reuters)
16th Nov 2005, 16:33 GMT
ImClone Systems Inc. said on Wednesday that a late-stage trial of its cancer drug Erbitux showed patients with head and neck cancer lived an average of 19.7 months longer than patients just treated with radiation.
ImClone drug extends life in head, neck cancer patients (Reuters) related news:
- ImClone drug extends life in head, neck cancer patients — Reuters: Health
- ImClone drug extends life in head and neck cancer (Reuters) —
- Erbitux produces survival benefit in head and neck cancer — Pharmaceutical Business Review Online
- Scots are given new breast cancer drug a year before England — Scotsman.com News - Health
- Scots given new breast cancer drug a year before England — Scotsman.com News
- Imclone Study Shows Head Cancer Benefit and U.S. BioDefense, Inc. Explores Strategic Response to Bird Flu — Financial News USA (OTC: FNWU)
- Combination treatment for brain cancer not detrimental to patients' quality of life — Medical News Today RSS/XML Feed
- Australian prostate cancer drug shows promise — KeralaNext: Science
- Cancer drug helps arthritis -- study (Reuters) — Yahoo! News: Health News
- Ovarian cancer patients' receptivity to therapy can be determined by genes — The Cancer Blog
Latest news from UNTITLED FEED:
- Simple steps can speed heart attack care: study (Reuters)
- Hospitals want faster heart attack care (Associated Press)
- Diabetes threatens many of world's indigenous people (Reuters)
- Fast test catches heart blockages, U.S. study shows (Reuters)
- Children showing hardening of arteries -U.S. study (Reuters)
- Children showing hardening of arteries: U.S. study (Reuters)
- Two Canada professors win right to toke up at work (Reuters)
- Results mixed on Merck's new painkiller (Associated Press)
- Group gives advice on face transplants (Associated Press)
- Diabetes drug may cut heart risks: study (Reuters)